A press release announced that the first two patients have enrolled in a trial of a treatment for Group 2 pulmonary hypertension (PH associated with left heart disease). The treatment procedure is minimally invasive and aims to reduce overactive nerve signals that might contribute to changes in the blood vessels in the lungs and to worsening heart and lung disease. Earlier studies confirmed that the procedure was safe and showed potential benefits. This procedure is also being explored to...

A small molecule called microRNA-224-5p (miR-224) appears to play an important role in the changes to the lung blood vessels that occur in pulmonary arterial hypertension (PAH). Researchers found that miR-224 levels were higher in cells from people with PAH and in several animal models, and that increasing miR-224 worsened the disease. In contrast, blocking miR-224 reduced abnormal blood vessel changes and improved right heart function in mice and rats. The researchers believe miR-224...

Researchers found that pre-treating pulmonary hypertension (PH) patients with dual therapy before they underwent balloon pulmonary angioplasty was associated with lower complications and better clinical outcomes, compared to mono therapy. Read the CHEST article